[1] 凯瑟琳·安妮·奎格利, 以斯拉·约翰·斯蒂尔, 伦纳德·杰西·池亚尔. 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基] -2H-酞嗪-1-酮:CN101821242[P]. 2010-09-01
[2] 陈本川. 治疗晚期卵巢癌新药:奥拉帕尼(olaparib)[J]. 医药导报, 2015, 34(6):846-849 CHEN Benchuan. Olaparib, a new drug for the treatment of advanced ovarian cancer[J]. Herald of Medicine, 2015, 34(6):846-849(in Chinese)
[3] 朱社凤. 一种奥拉帕利组合物胶囊:CN107375232A[P]. 2017-11-24
[4] 刘振腾,孙逸威,李华,等. 一种奥拉帕利化合物的合成方法:CN107325055A[P].2017-11-07
[5] 章微华,蔡鸿飞,金远锋. 一种奥拉帕利的重结晶方法:CN107304187A[P].2017-10-31
[6] 赵绍磊, 王灵宇, 吴送姑. 药物多晶型的研究进展[J]. 化学工业与工程, 2018, 35(3):12-21 ZHAO Shaolei, WANG Lingyu, WU Songgu. Progress in the research of pharmaceutical polymorph[J]. Chemical Industry and Engineering, 2018, 35(3):12-21(in Chinese)
[7] 朱社凤. 一种治疗卵巢癌的药物奥拉帕利的制备方法:CN107382873A[P]. 2017-11-24
[8] 陈敏华, 张炎锋, 刘凯,等. 奥拉帕利与尿素的共晶及其制备方法:CN105753789A[P]. 2016-07-13
[9] 陈嘉媚, 高璐, 戴霞林. 一种奥拉帕利与富马酸共晶晶型α及其制备方法与应用:CN202110925622[P]. 2021-10-09
[10] BēRZI A, REKIS T, ACTI A. Comparison and rationalization of droperidol isostructural solvate stability:An experimental and computational study[J]. Crystal Growth & Design, 2014, 14(7):3639-3648
[11] XU W, GONG N, YANG S, et al. Isostructurality among solvates of cabazitaxel:X-ray structures and new solvates preparation[J]. Journal of Pharmaceutical Sciences, 2015, 104(4):1256-1262
[12] YANG D, GONG N, ZHANG L, et al. Isostructurality among 5 solvatomorphs of betulin:X-ray structure and characterization[J]. Journal of Pharmaceutical Sciences, 2016, 105(6):1867-1873
[13] GALLAGHER J F, MOCILAC P. Pockets and channels in tennimide solvate structures:Influence of solvent on crystal packing behaviour[J]. Journal of Molecular Structure, 2021, doi:10.1016/j.molstruc.2021.130149
[14] 冉媛媛. 克林霉素磷酸酯溶剂化物转化研究[D]. 天津:天津大学, 2014 RAN Yuanyuan. Study on the transformation of solvates of clindamycin phosphate[D]. Tianjin:Tianjin University, 2014 (in Chinese)
[15] BURNS D H, CARPER W R. Anion recognition in a model ion channel:Effects of solvation on chloride binding to a porphyrin-metacyclophane[J]. Journal of Molecular Structure:THEOCHEM, 2004, 711(1/2/3):149-157
[16] TOMASI J, MENNUCCI B, CAMMI R. Quantum mechanical continuum solvation models[J]. Chemical Reviews, 2005, 105(8):2999-3094
[17] 倪维骅. 药物多晶型的研究方法[J]. 医药工业, 1981, 12(9):33-39, 5, 50 NI Weihua. Research methods of drug polymorphism[J]. Chinese Journal of Pharmaceuticals, 1981, 12(9):33-39, 5, 50(in Chinese)
[18] GIRON D. Thermal analysis and calorimetric methods in the characterisation of polymorphs and solvates[J]. Thermochimica Acta, 1995, 248:1-59
[19] LABUZA T, ALTUNAKAR B. Water activity prediction and moisture sorption isotherms[J]. Water Activity in Foods:Fundamentals and Applications, 2020:161-205
[20] WANG X, WU S, DONG W, et al. In situ monitoring of the solvent-mediated transformation of cefadroxil DMF solvate into monohydrate[J]. Organic Process Research & Development, 2013, 17(9):1110-1116
[21] 刘雅. L-组氨酸伴随多晶型及晶型转化过程研究[D]. 天津:天津大学, 2018 LIU Ya. A study on concomitant polymorphism and solution-mediated phase transformation of L-histidine in antisolvent crystallization[D]. Tianjin:Tianjin University, 2018 (in Chinese)
[22] HERMAN C, HAUT B, DOUIEB S, et al. Use of in Situ Raman, FBRM, and ATR-FTIR probes for the understanding of the solvent-mediated polymorphic transformation of Ⅱ-Ⅰ etiracetam in methanol[J]. Organic Process Research & Development, 2012, 16(1):49-56
[23] O'MAHONY M A, MAHER A, CROKER D M, et al. Examining solution and solid state composition for the solution-mediated polymorphic transformation of carbamazepine and piracetam[J]. Crystal Growth & Design, 2012, 12(4):1925-1932
[24] GU C, YOUNG V J, GRANT D J W. Polymorph screening:Influence of solvents on the rate of solvent-mediated polymorphic transformation[J]. Journal of Pharmaceutical Sciences, 2001, 90(11):1878-1890
[25] CARDEW P T, DAVEY R J. The kinetics of solvent-mediated phase transformations[J]. Proceedings of the Royal Society of London A Mathematical and Physical Sciences, 1985, 398(1815):415-428
|
2023, Vol. 40 
